Gland Pharma Limited — Q1 FY26
Gland Pharma reported a solid Q1 FY26 with consolidated revenue of INR 1,506 crore (+7% YoY) and EBITDA of INR 368 crore (+39% YoY), driving margins to 24% (up 500bps YoY).
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q4 FY25
Cenexi positive EBITDA by Q3 FY26
Cenexi is targeting to achieve positive EBITDA by the third quarter of FY26, with double-digit EBITDA margins expected in FY27.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1